Intranasal Treatment of Central Nervous System Dysfunction in HumansReport as inadecuate

Intranasal Treatment of Central Nervous System Dysfunction in Humans - Download this document for free, or read online. Document in PDF available to download.

Pharmaceutical Research

, Volume 30, Issue 10, pp 2475–2484

First Online: 08 November 2012Received: 27 July 2012Accepted: 12 October 2012 ABSTRACT

One of the most challenging problems facing modern medicine is how to deliver a given drug to a specific target at the exclusion of other regions. For example, a variety of compounds have beneficial effects within the central nervous system CNS, but unwanted side effects in the periphery. For such compounds, traditional oral or intravenous drug delivery fails to provide benefit without cost. However, intranasal delivery is emerging as a noninvasive option for delivering drugs to the CNS with minimal peripheral exposure. Additionally, this method facilitates the delivery of large and-or charged therapeutics, which fail to effectively cross the blood-brain barrier BBB. Thus, for a variety of growth factors, hormones, neuropeptides and therapeutics including insulin, oxytocin, orexin, and even stem cells, intranasal delivery is emerging as an efficient method of administration, and represents a promising therapeutic strategy for the treatment of diseases with CNS involvement, such as obesity, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, depression, anxiety, autism spectrum disorders, seizures, drug addiction, eating disorders, and stroke.

KEY WORDScentral nervous system insulin intranasal administration oxytocin stem cells  Download fulltext PDF

Author: Colin D. Chapman - William H. FreyII - Suzanne Craft - Lusine Danielyan - Manfred Hallschmid - Helgi B. Schiöth - Christ


Related documents